CA2207593A1 - Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunes - Google Patents
Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunesInfo
- Publication number
- CA2207593A1 CA2207593A1 CA002207593A CA2207593A CA2207593A1 CA 2207593 A1 CA2207593 A1 CA 2207593A1 CA 002207593 A CA002207593 A CA 002207593A CA 2207593 A CA2207593 A CA 2207593A CA 2207593 A1 CA2207593 A1 CA 2207593A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- rna
- ribozyme
- chemically reactive
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24017—Stromelysin 1 (3.4.24.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Abstract
Molécule d'acide nucléique enzymatique effectuant le clivage de l'ARN associé à l'évolution ou à l'existence d'un état arthritique, à l'introduction d'une tolérance aux greffes ou à l'inversion d'une réaction immune. En particulier, les séquences de ribozymes sont dirigées vers un ARNm codant B7-1, B7-3, cd40 et/ou stromelysine. L'invention concerne également des ribozymes où uracil des positions 4 et/ou 7 est substitué, ainsi que des procédés de synthèse de 2'-alkylnucléotides, 2'-O-alkylthioalkyle ou 2'-alkylnucléotides, 2'-O-alkylthioalkyle ou 2'-alkylthioalkylnucléotides. Elle concerne, de plus, un procédé de déprotection de l'ARN par éthylamine aqueux, un procédé de synthèse de produits mimétiques de ribonucléosides de base, ainsi que des unités de transcription composés d'un promoteur de polymérase II d'ARN, d'un promoteur nucléaire réduit de U6 ou d'un système promoteur de VA1 d'adénovirus.
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35492094A | 1994-12-13 | 1994-12-13 | |
US08/354,920 | 1994-12-13 | ||
US08/363,253 US5891683A (en) | 1993-09-02 | 1994-12-23 | Non-nucleotide containing enzymatic nucleic acid |
US08/363,253 | 1994-12-23 | ||
US08/363,254 US5891684A (en) | 1992-10-15 | 1994-12-23 | Base-modified enzymatic nucleic acid |
US08/363,254 | 1994-12-23 | ||
US08/390,850 US5612215A (en) | 1992-12-07 | 1995-02-17 | Stromelysin targeted ribozymes |
US08/390,850 | 1995-02-17 | ||
US08/426,124 US5716824A (en) | 1995-04-20 | 1995-04-20 | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
US08/426,124 | 1995-04-20 | ||
US08/432,874 | 1995-05-02 | ||
US08/432,874 US5627053A (en) | 1994-03-29 | 1995-05-02 | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US43450995A | 1995-05-04 | 1995-05-04 | |
US08/434,509 | 1995-05-04 | ||
US60/000,974 | 1995-07-07 | ||
US60/000,951 | 1995-07-07 | ||
US08/512,861 US6146886A (en) | 1994-08-19 | 1995-08-07 | RNA polymerase III-based expression of therapeutic RNAs |
US08/512,861 | 1995-08-07 | ||
US08/541,365 US5672501A (en) | 1994-12-23 | 1995-10-05 | Base-modified enzymatic nucleic acid |
US08/541,365 | 1995-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2207593A1 true CA2207593A1 (fr) | 1996-06-20 |
Family
ID=56289667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002207593A Abandoned CA2207593A1 (fr) | 1994-12-13 | 1995-11-22 | Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunes |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4412096A (fr) |
CA (1) | CA2207593A1 (fr) |
WO (1) | WO1996018736A2 (fr) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69633272T2 (de) * | 1995-02-08 | 2005-09-08 | Takara Bio Inc., Otsu | Methoden zur Krebsbehandlung und -kontrolle |
US5807743A (en) * | 1996-12-03 | 1998-09-15 | Ribozyme Pharmaceuticals, Inc. | Interleukin-2 receptor gamma-chain ribozymes |
CA2275964A1 (fr) * | 1996-12-24 | 1998-07-02 | Ribozyme Pharmaceuticals, Inc. | Synthese chimique d'analogues de nucleosides et leur incorporation dans des polynucleotides |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6319906B1 (en) * | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
WO1998050530A2 (fr) * | 1997-05-09 | 1998-11-12 | Ribozyme Pharmaceuticals, Inc. | Traitement a l'acide nucleique enzymatique de maladies et etats pathologiques associes aux niveaux d'expression de c-raf |
US6548657B1 (en) | 1997-06-09 | 2003-04-15 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
US6280936B1 (en) | 1997-06-09 | 2001-08-28 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
US6183959B1 (en) | 1997-07-03 | 2001-02-06 | Ribozyme Pharmaceuticals, Inc. | Method for target site selection and discovery |
US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
WO1999016871A2 (fr) * | 1997-09-22 | 1999-04-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissensc | Acides nucleiques catalyseurs a activite d'endonuclease |
US6656731B1 (en) | 1997-09-22 | 2003-12-02 | Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acid catalysts with endonuclease activity |
US6127535A (en) * | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
JP2003525017A (ja) | 1998-04-20 | 2003-08-26 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 遺伝子発現を調節しうる新規な化学組成を有する核酸分子 |
AU751480B2 (en) * | 1998-04-29 | 2002-08-15 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into ribozymes |
EP1493818A3 (fr) * | 1998-04-29 | 2006-02-15 | Ribozyme Pharmaceuticals, Inc. | Nucléosides triphosphates et leur intégration aux ribozymes |
EP1114827B1 (fr) * | 1999-07-15 | 2010-11-17 | Japan Science and Technology Agency | Nouvelle paire de bases d'acide nucleique |
US6831171B2 (en) | 2000-02-08 | 2004-12-14 | Yale University | Nucleic acid catalysts with endonuclease activity |
US7125660B2 (en) | 2000-09-13 | 2006-10-24 | Archemix Corp. | Nucleic acid sensor molecules and methods of using same |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7132529B2 (en) * | 2001-07-30 | 2006-11-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
US20050043256A1 (en) | 2001-07-30 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP2258847B2 (fr) | 2002-08-05 | 2020-07-01 | Silence Therapeutics GmbH | Autres nouvelles formes de molécules d'ARN interférant |
AU2012216354B2 (en) * | 2002-08-05 | 2016-01-14 | Silence Therapeutics Gmbh | Further novel forms of interfering RNA molecules |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7732591B2 (en) | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
US7960355B2 (en) | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
US7897582B2 (en) | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
JP4682152B2 (ja) | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2006009575A1 (fr) | 2004-06-22 | 2006-01-26 | The Board Of Trustees Of The University Of Illinois | Procedes pour inhiber la proliferation des cellules tumorales avec foxm1 arnsi |
JP5192807B2 (ja) * | 2005-06-24 | 2013-05-08 | ヤマサ醤油株式会社 | シュードウリジン保護体の安定結晶 |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
DK2578685T3 (da) | 2005-08-23 | 2019-06-03 | Univ Pennsylvania | Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf |
CN101321775B (zh) | 2005-10-03 | 2012-05-23 | 大学健康网络 | 用于治疗疟疾的odcase抑制剂 |
US8669345B2 (en) | 2006-01-27 | 2014-03-11 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
US7741469B2 (en) | 2006-04-05 | 2010-06-22 | University Of Iowa Research Foundation | Compositions for treating hearing loss and methods of use thereof |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
EP4082551A1 (fr) | 2006-08-08 | 2022-11-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Structure et utilisation d'oligonucléotides 5'-phosphate |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
EP2297323A1 (fr) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | Oligonucléotide à 5 -triphosphate présentant une extrémité franche et ses utilisations |
CN102439151A (zh) | 2009-03-19 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制 |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2408915A2 (fr) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | Inhibition induite par arn interférence d'une expression génique (gata3) d'une protéine de liaison gata au moyen d'un acide nucléique interférent court |
SG174581A1 (en) | 2009-03-27 | 2011-10-28 | Merck Sharp & Dohme | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411019A2 (fr) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Inhibition par interférence arn de l'expression du gène du signal transducteur et activateur de la transcription 1 (stat1) au moyen d'un acide nucléique interférent court (ansi) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111464A1 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi) |
WO2010111468A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI) |
US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
CA2781896C (fr) | 2009-12-09 | 2021-03-30 | Nitto Denko Corporation | Modulation de l'expression de hsp47 |
AU2011255203B2 (en) | 2010-05-21 | 2016-01-21 | Peptimed, Inc. | Reagents and methods for treating cancer |
SG186438A1 (en) | 2010-06-24 | 2013-01-30 | Quark Pharmaceuticals Inc | Double stranded rna compounds to rhoa and use thereof |
CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制 |
KR102072631B1 (ko) | 2010-08-17 | 2020-02-03 | 시르나 쎄러퓨틱스 인코퍼레이티드 | 짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제 |
EP3372684B1 (fr) | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Agents d'arni à un seul brin contenant un espaceur interne d'acide non nucléique |
EP2609106A4 (fr) | 2010-08-26 | 2014-03-19 | Merck Sharp & Dohme | Inhibition médiée par interférence arn de l'expression du gène phd2 (prolyl hydroxylase domaine 2) utilisant un petit acide nucléique interférent (pani) |
EP3766975A1 (fr) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
KR20130103562A (ko) | 2010-11-01 | 2013-09-23 | 펩타임드, 인코포레이티드 | 암을 치료하기 위한 펩티드 표적화 시스템의 조성물 |
CA2828002A1 (fr) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions et procedes pour traiter des maladies et des lesions pulmonaires |
EP2508530A1 (fr) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification d'oligonucléotides triphosphorylés au moyen d'étiquettes de capture |
TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Hsp47表現調控強化用類視色素脂質體 |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
CN104080912A (zh) | 2012-01-12 | 2014-10-01 | 夸克制药公司 | 用于治疗听力和平衡障碍的组合疗法 |
DK2895608T3 (en) | 2012-09-12 | 2019-01-21 | Quark Pharmaceuticals Inc | DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT |
EP2712870A1 (fr) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nouveaux ligands de RIG-I et procédés pour les produire |
WO2023097308A1 (fr) | 2021-11-29 | 2023-06-01 | Hongene Biotech Corporation | Synthèse de nucléosides protégés 2' acétyl-ester |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69133405T2 (de) * | 1990-01-11 | 2005-07-07 | Isis Pharmaceutical, Inc., Carlsbad | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression |
DE4216134A1 (de) * | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
WO1993023569A1 (fr) * | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif d'inhibition de la replication virale |
WO1994002595A1 (fr) * | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif pour le traitement de maladies chez les animaux |
WO1995004818A1 (fr) * | 1993-08-06 | 1995-02-16 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif servant a inhiber la replication du virus de l'immunodeficience humaine |
CA2176035A1 (fr) * | 1993-11-08 | 1995-05-18 | Nassim Usman | Acide nucleique enzymatique a modification de base |
DE69431564D1 (de) * | 1993-11-12 | 2002-11-21 | Ribozyme Pharm Inc | Reagenz zur behandlung von arthritischen zustaenden |
EP0746614A1 (fr) * | 1994-02-23 | 1996-12-11 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif inhibiteur de l'expression de genes concernant une affection |
-
1995
- 1995-11-22 AU AU44120/96A patent/AU4412096A/en not_active Abandoned
- 1995-11-22 WO PCT/US1995/015516 patent/WO1996018736A2/fr not_active Application Discontinuation
- 1995-11-22 CA CA002207593A patent/CA2207593A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1996018736A3 (fr) | 1996-09-19 |
AU4412096A (en) | 1996-07-03 |
WO1996018736A2 (fr) | 1996-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2207593A1 (fr) | Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunes | |
US6365374B1 (en) | 2′-deoxy-2′-alkylnucleotide containing nucleic acid | |
US6159692A (en) | Method and reagent for inhibiting human immunodeficiency virus replication | |
AU706417B2 (en) | Method and reagent for inhibiting the expression of disease related genes | |
US7034009B2 (en) | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) | |
US5877021A (en) | B7-1 targeted ribozymes | |
EP0725788B1 (fr) | 2'-amido et 2'-peptido oligonucleotides modifies | |
US6017756A (en) | Method and reagent for inhibiting hepatitis B virus replication | |
US5989906A (en) | Method and reagent for inhibiting P-glycoprotein (mdr-1-gene) | |
US20020193579A1 (en) | Non-nucleotide containing enzymatic nucleic acid | |
EP1251170A2 (fr) | Procédé et réactif pour le traitement de maladies animales dépendants de NF-kappaB | |
US5750390A (en) | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene | |
CA2304813A1 (fr) | Acides nucleiques catalyseurs a activite d'endonuclease | |
CA2222793A1 (fr) | Minizymes et miniribozymes optimises et utilisation de ces derniers | |
US6368855B1 (en) | MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression | |
EP0948511A2 (fr) | Synthese chimique d'analogues de nucleosides et leur incorporation dans des polynucleotides | |
WO1998043993A2 (fr) | Acides nucleiques en tant que catalyseurs | |
WO1995004818A1 (fr) | Procede et reactif servant a inhiber la replication du virus de l'immunodeficience humaine | |
US5616490A (en) | Ribozymes targeted to TNF-α RNA | |
US6528639B2 (en) | Base-modified enzymatic nucleic acid | |
US5599704A (en) | ErbB2/neu targeted ribozymes | |
US5807743A (en) | Interleukin-2 receptor gamma-chain ribozymes | |
US5672501A (en) | Base-modified enzymatic nucleic acid | |
CA2398750A1 (fr) | Nucleozymes a activite d'endonuclease | |
US6656731B1 (en) | Nucleic acid catalysts with endonuclease activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |